Author: admin

DelveInsight’s, Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report

• June 2024:-Neal Ready MD PhD- This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may enhance the ability of the immune system to fight off cancer. The study will investigate the effects of pembrolizumab on the immune system and how certain immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab. Previous studies suggest that pembrolizumab could alter the immune cells in a way that the the immune cells identify cancer cells.
• June 2024:- Merck Sharp & Dohme LLC-A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer. The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%, TPS ≥1% and TPS 1% to 49%; and (2) progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), in participants with PD-L1 TPS ≥1% and TPS ≥50%.
• DelveInsight’s Non-Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Non-Small Cell Lung Cancer treatment.
• The leading Non-Small Cell Lung Cancer Companies such as Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech, and others.
• Promising Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.

Stay informed about the cutting-edge advancements in Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ Non-Small Cell Lung Cancer Clinical Trials Assessment

Non-Small-Cell Lung cancer (NSCLC) Drugs

• V940: Merck Sharp & Dohme LLC

V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumor. It is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient’s tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. The drug is in Phase III stage for the treatment of NSCLC.

• QL1706: Qilu Pharmaceutical Co., Ltd.

QL1706 is an investigational bifunctional antibody with additional anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody could increase the anti-tumor effect of anti-programmed cell death 1 (PD-1) antibody. QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA4 IgG1 antibodies produced by a single cell line. The drug is in Phase III stage for the treatment of NSCLC.

• Zenocutuzumab (MCLA-128): Merus N.V.

Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. It has a dual mechanism against cancer, as it prevents NRG1 fusions from binding to the protein HER3 and it blocks the interaction of HER3 with HER2, which the cancer cells depend on to survive and multiply. Currently, the drug is in Phase II stage for the treatment of NSCLC.

• ZW49: Zymeworks BC Inc.

ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload. A biparatopic (targeting two different non-overlapping epitopes on ERBB2, on extracellular domains 2 (ECD2) and 4 (ECD4). ZW25 is an anti-HER2 biparatopic antibody which binds to the same domains as trastuzumab and pertuzumab. ZW25 simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent effector function. ZW49 is in Phase I of clinical trials for the treatment of non-small cell lung cancer.

Learn more about Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking Non-Small Cell Lung Cancer Research and development projects @ Non-Small Cell Lung Cancer Unmet Needs

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non-Small Cell Lung Cancer Companies- Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech, and others.
• Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Non-Small Cell Lung Cancer Pipeline on our website @ Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Non-Small-Cell Lung cancer (NSCLC) : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. V940: Merck Sharp & Dohme LLC
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Zenocutuzumab (MCLA-128): Merus N.V.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ZW49: Zymeworks BC Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Non-Small-Cell Lung cancer (NSCLC) Key Companies
21. Non-Small-Cell Lung cancer (NSCLC) Key Products
22. Non-Small-Cell Lung cancer (NSCLC) – Unmet Needs
23. Non-Small-Cell Lung cancer (NSCLC) – Market Drivers and Barriers
24. Non-Small-Cell Lung cancer (NSCLC) – Future Perspectives and Conclusion
25. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
26. Non-Small-Cell Lung cancer (NSCLC) Key Companies
27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in HER2-mutant Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ HER2-mutant Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report

• May 2024:- M.D. Anderson Cancer Center– This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
• April 2024:- AstraZeneca- An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05). The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
• DelveInsight’s HER2-mutant Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for HER2-mutant Non-Small Cell Lung Cancer treatment.
• The leading HER2-mutant Non-Small Cell Lung Cancer Companies such as Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc., and others.
• Promising HER2-mutant Non-Small Cell Lung Cancer Therapies such as Trastuzumab deruxtecan, Poziotinib, and others.

Stay informed about the cutting-edge advancements in HER2-mutant Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ HER2-mutant Non-Small Cell Lung Cancer Clinical Trials Assessment

HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile

• DZD-9008: Dizal Pharmaceuticals

DZD9008 is a selective, irreversible EGFR inhibitor, which is currently being evaluated for the treatment of both EGFRexon20 insertion mutation-positive NSCLC and HER2-mutated NSCLC. In the open-label, multicenter phase I/II study (NCT03974022), 220 patients with EGFRexon20 insertion mutation-positive or HER2-positive NSCLC were treated with DZD9008 at doses of 50 mg to 400 mg once daily.

• Enhertu: AstraZeneca

Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens based on the results from the DESTINY-Breast01 trial. Enhertu (6.4mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastro esophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

• Pyrotinib: Jiangsu Hengrui Medicine

Pyrotinib is a novel irreversible and selective EGFR/HER2 tyrosine kinase inhibitor developed by Hengrui. In 2018, pyrotinib was approved in China in combination with capecitabine for the treatment of relapsed or metastatic HER2-positive breast cancer. Currently, two Phase III studies are ongoing to evaluate pyrotinib as 1st-line treatment (NCT03863223) and extended adjuvant treatment (NCT03980054), respectively in HER2-positive breast cancer patients. In addition to breast cancer, pyrotinib demonstrated superior clinical benefits in advanced non-small cell lung cancer (NSCLC) with HER2 exon 20 mutation in a Phase II study. A global Phase III study (NCT04447118) is ongoing to investigate pyrotinib in patients with advanced non-squamous NSCLC with HER2 exon 20 mutation who previously failed platinum-based chemotherapy.

Learn more about HER2-mutant Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking HER2-mutant Non-Small Cell Lung Cancer Research and development projects @ HER2-mutant Non-Small Cell Lung Cancer Unmet Needs

HER2-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HER2-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in HER2-mutant Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ HER2-mutant Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• HER2-mutant Non-Small Cell Lung Cancer Companies- Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc., and others.
• HER2-mutant Non-Small Cell Lung Cancer Therapies- Trastuzumab deruxtecan, Poziotinib, and others.
• HER2-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of HER2-mutant Non-Small Cell Lung Cancer Pipeline on our website @ HER2-mutant Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. HER2-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-mutant Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Enhertu: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. DZD-9008: Dizal Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2-mutant Non-Small Cell Lung Cancer Key Companies
21. HER2-mutant Non-Small Cell Lung Cancer Key Products
22. HER2-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. HER2-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. HER2-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. HER2-mutant Non-Small Cell Lung Cancer Analyst Views
26. HER2-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-mutant Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK-positive Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in ALK-positive Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report

• June 2024:- Pfizer- Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI). The purpose of this clinical trial is to learn whether the study medicine (called lorlatinib) is safe and effective for the treatment of non-small cell lung cancer that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene.
• June 2024:- Takeda- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®). The drug being tested in this study is called brigatinib. Brigatinib has been demonstrated to benefit people with anaplastic lymphoma kinase-positive (ALK+) NSCLC.
• June 2024:- Hoffmann-La Roche- The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
• June 2024:- AstraZeneca- Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments. A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
• DelveInsight’s ALK-positive Non-Small Cell Lung Cancer pipeline report depicts a robust space with 6+ active players working to develop 7+ pipeline therapies for ALK-positive Non-Small Cell Lung Cancer treatment.
• The leading ALK-positive Non-Small Cell Lung Cancer Companies such as Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.
• Promising ALK-positive Non-Small Cell Lung Cancer Therapies such as Crizotinib, XZP-3621, Gefitinib, Savolitinib, Osimertinib, TGRX-326, and others.

Stay informed about the cutting-edge advancements in ALK-positive Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ ALK-positive Non-Small Cell Lung Cancer Clinical Trials Assessment

ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile

• SY-3505: Shouyao Holdings

Ficonalkib (SY-3505) is a highly potent, adenosine triphosphate-competitive, CNS-penetrant, 3rd-gen ALK TKI. In vitro kinase assay revealed that ficonalkib exhibits potent inhibition against both wild-type ALK and a diverse spectrum of mutants observed in patients resistant to 1st- and 2nd-gen ALK TKI, including L1196M, G1202R, F1174L, G1269S, and R1275Q20. The drug exhibits high kinase selectivity and has very weak inhibition on tropomyosin receptor kinase (TRK). The drug is currently being evaluated under Phase III clinical trials for the treatment of NSCLC.

• APG-2449: Ascentage Pharma

APG-2449 is an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development. The updated results at the ASCO indicated favorable safety and promising antitumor activity in patients with NSCLC, and the preliminary efficacy observed in patients who were resistant to second-generation ALK inhibitors was particularly encouraging. APG-2449 is currently being evaluated in Phase I clinical trial for Non-Small Cell Lung Cancer.

Learn more about ALK-positive Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking ALK-positive Non-Small Cell Lung Cancer Research and development projects @ ALK-positive Non-Small Cell Lung Cancer Unmet Needs

ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

ALK-positive Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in ALK-positive Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ ALK-positive Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• ALK-positive Non-Small Cell Lung Cancer Companies- Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.
• ALK-positive Non-Small Cell Lung Cancer Therapies- Crizotinib, XZP-3621, Gefitinib, Savolitinib, Osimertinib, TGRX-326, and others.
• ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of ALK-positive Non-Small Cell Lung Cancer Pipeline on our website @ ALK-positive Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. ALK Positive Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. ALK Positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. SY-3505: Shouyao Holdings
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Product Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. APG-2449: Ascentage Pharma
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. ALK Positive Non-Small Cell Lung Cancer – Collaborations Assessment- Licensing / Partnering / Funding
21. ALK Positive Non-Small Cell Lung Cancer – Unmet Needs
22. ALK Positive Non-Small Cell Lung Cancer – Market Drivers and Barriers
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ALK-positive Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the C-MET Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in C-MET Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ C-MET Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the C-MET Non-Small Cell Lung Cancer Pipeline Report

• June 2024:- AbbVie– A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
• May 2024: Apollomics Inc.- Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.
• DelveInsight’s C-MET Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for C-MET Non-Small Cell Lung Cancer treatment.
• The leading C-MET Non-Small Cell Lung Cancer Companies such as Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others.
• Promising C-MET Non-Small Cell Lung Cancer Therapies such as Glumetinib, Telisotuzumab vedotin, Tepotinib, APL-101 Oral Capsules, MCLA-129, Osimertinib, PLB1001, and others.

Stay informed about the cutting-edge advancements in C-MET Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ C-MET Non-Small Cell Lung Cancer Clinical Trials Assessment

C-MET Non-Small Cell Lung Cancer Emerging Drugs Profile

• EGF-816 (Nazartinib): Novartis Oncology

Novarti’s lead drug candidate, EGF-816 (Nazartinib), is small molecule in combination with INC280 is in development for the treatment of non-small cell lung cancer. Clinical trials data demonstrated that EGF-816 (Nazartinib) for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) has beneficial effects. The drug is a new molecule which is an epidermal growth factor receptor antagonist that blocks the function of protein EGFR.

• APL 101 (Bozitinib): Appolomics Inc.

Apollomics drug APL 101 (Bozitinib) is an orally administered small molecule currently being evaluated for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and has demonstrated good safety and efficacy profile in phase II trials. APL 101 (Bozitinib) is an anti-neoplastics which inhibits the C-met protein.

Learn more about C-MET Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking C-MET Non-Small Cell Lung Cancer Research and development projects @ C-MET Non-Small Cell Lung Cancer Unmet Needs

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

C-MET Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Discover the latest advancements in C-MET Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ C-MET Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the C-MET Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• C-MET Non-Small Cell Lung Cancer Companies- Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others.
• C-MET Non-Small Cell Lung Cancer Therapies- Glumetinib, Telisotuzumab vedotin, Tepotinib, APL-101 Oral Capsules, MCLA-129, Osimertinib, PLB1001, and others.
• C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of C-MET Non-Small Cell Lung Cancer Pipeline on our website @ C-MET Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Collaboration Deals
9. Late Stage Products (Phase III)
10. EGF 816 (Nazartinib): Novartis
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. APL 101 (Bozitinib): Apollomics Inc.
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
19. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Products
20. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Unmet Needs
21. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Market Drivers and Barriers
22. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Future Perspectives and Conclusion
23. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Analyst Views
24. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: C-MET Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) Pipeline Insight 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the BRAF-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in BRAF-mutant Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ BRAF-mutant Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report

• April 2024:- Pfizer– This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
• April 2024:- Immuneering Corporation- A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations. This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.
• DelveInsight’s BRAF-mutant Non-Small Cell Lung Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for BRAF-mutant Non-Small Cell Lung Cancer treatment.
• The leading BRAF-mutant Non-Small Cell Lung Cancer Companies such as Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
• Promising BRAF-mutant Non-Small Cell Lung Cancer Therapies such as IMM-6-415, binimetinib, encorafenib, Trametinib, Dabrafenib, and others.

Stay informed about the cutting-edge advancements in BRAF-mutant Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ BRAF-mutant Non-Small Cell Lung Cancer Clinical Trials Assessment

BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile

• Encorafenib/Binimetinib: Pierre Fabre Medicament

BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The combination is currently investigated in Metastatic BRAFV600-mutant Non-Small Cell Lung Cancer in Phase II trial with completion expected in March 2025. This combination is indicated and being tested for several other indications.

• XP-102: Xynomic Pharmaceuticals, Inc.

XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia. The drug is currently being investigated for several tumor including non-small cell lung cancer in Phase I/II which is expected to be completed by December 2024.

Learn more about BRAF-mutant Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking BRAF-mutant Non-Small Cell Lung Cancer Research and development projects @ BRAF-mutant Non-Small Cell Lung Cancer Unmet Needs

BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

BRAF-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in BRAF-mutant Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ BRAF-mutant Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• BRAF-mutant Non-Small Cell Lung Cancer Companies- Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
• BRAF-mutant Non-Small Cell Lung Cancer Therapies- IMM-6-415, binimetinib, encorafenib, Trametinib, Dabrafenib, and others.
• BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of BRAF-mutant Non-Small Cell Lung Cancer Pipeline on our website @ BRAF-mutant Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. BRAF-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. BRAF-mutant Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Encorafenib/Binimetinib: Pierre Fabre Medicament
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. XP-102: Xynomic Pharmaceuticals, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
21. BRAF-mutant Non-Small Cell Lung Cancer Key Products
22. BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
26. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BRAF-mutant Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Relapsed/Refractory Acute Myeloid Leukemia Research. Learn more about our innovative pipeline today! @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook

Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

• June 2024:- Ryvu Therapeutics SA- A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent.
• June 2024:- LLS PedAL Initiative LLC- A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
• DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/Refractory Acute Myeloid Leukemia treatment.
• The leading Relapsed/Refractory Acute Myeloid Leukemia Companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
• Promising Relapsed/Refractory Acute Myeloid Leukemia Therapies such as UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.

Stay informed about the cutting-edge advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatments. Download for updates and be a part of the revolution in oncology care @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials Assessment

Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs Profile

• APG-2575: Ascentage Pharma

APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).

• CLN 049: Cullinan Oncology

CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.

• Lanraplenib: Kronos Bio

Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.

Learn more about Relapsed/Refractory Acute Myeloid Leukemia Drugs opportunities in our groundbreaking Relapsed/Refractory Acute Myeloid Leukemia Research and development projects @ Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs

Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives

Relapsed/Refractory Acute Myeloid Leukemia Market Drivers

• Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Relapsed/Refractory Acute Myeloid Leukemia Market.

Relapsed/Refractory Acute Myeloid Leukemia Market Barriers

• However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Relapsed/Refractory Acute Myeloid Leukemia Market growth.

Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

• Coverage- Global
• Relapsed/Refractory Acute Myeloid Leukemia Companies- Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
• Relapsed/Refractory Acute Myeloid Leukemia Therapies- UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Relapsed/Refractory Acute Myeloid Leukemia Pipeline on our website @ Relapsed/Refractory Acute Myeloid Leukemia Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Relapsed/refractory acute myeloid leukemia (AML): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsed/refractory acute myeloid leukemia (AML)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. APG-2575: Ascentage Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CLN 049: Cullinan Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
21. Relapsed/refractory acute myeloid leukemia (AML) Key Products
22. Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
23. Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
24. Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
25. Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
26. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight